94. Thakur M Das, Stuart DD. Molecular pathways: response and
resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.
Clin Cancer Res 2014;20:1074–80.
95. Tumeh PC, Harview CL, Yearley JH, et al. PD- 1 blockade induces
responses by inhibiting adaptive immune resistance. Nature
96. Ayers M, Lunceford J, Nebozhyn M, et al. Relationship between
immune gene signatures and clinical response to PD- 1 blockade
with pembrolizumab (MK-3475) in patients with advanced solid
tumors. J Immunotherapy Cancer 2015; 3(Suppl 2):P80.
Board Review Questions
Download the Free
Hematology/Oncology App at: